login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
EYEPOINT PHARMACEUTICALS INC (EYPT) Stock News
USA
- NASDAQ:EYPT -
US30233G2093
-
Common Stock
11.63
USD
+0.08 (+0.69%)
Last: 10/17/2025, 8:08:56 PM
11.63
USD
0 (0%)
After Hours:
10/17/2025, 8:08:56 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
EYPT Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
4 days ago - By: Benzinga
- Mentions:
OMER
AKTX
SSKN
GNPX
...
12 Health Care Stocks Moving In Wednesday's Intraday Session
4 days ago - By: Benzinga
- Mentions:
REGN
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study
5 days ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Announces Pricing of Public Offering
5 days ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Announces Proposed Public Offering of Common Stock
5 days ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema
2 months ago - By: The Motley Fool
- Mentions:
AMD
EyePoint (EYPT) Q2 Revenue Drops 44%
a month ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Announces Participation at Upcoming Investor Conferences
2 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2 months ago - By: Zacks Investment Research
- Mentions:
COYA
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
2 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
2 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments
3 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
3 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
3 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
4 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Announces Participation at Upcoming Investor Conferences
5 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
5 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6 months ago - By: Zacks Investment Research
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say
6 months ago - By: Zacks Investment Research
- Mentions:
STRO
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates
6 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments
6 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025
6 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
7 months ago - By: EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Please enable JavaScript to continue using this application.